(ii) OMP-59R5, an anti-Notch2/3 mAb, has been tested in clinical trials in solid tumor [32], stage IV pancreatic cancer [33], and stage IV small cell lung cancer (SCLC). This evidence concerns the gene NOTCH2 and small cell lung carcinoma.